IMMUNE NETWORK RESEARCH LTD.
IMM : VSE
NewsNOW! Automatic E-mail Alert
Monday, December 21, 1998
NEWS RELEASE:
ANTIBODY PATENT ISSUED
VANCOUVER, BC - Victor Jones, President, is very pleased to
report that the United States Patent Office has issued a patent
covering monoclonal antibody 1F7 ("mAb 1F7") as United States
Patent No. 5,849,583 titled Anti-idiotypic Antibody And Its Use In
Diagnosis And Therapy In HIV-Related Disease. The patent office
abstract states-, "The present invention provides an anti-idiotypic
antibody having specific reactivity with an idiotope common to more
than one type of anti-HIV-1 antibody, and having no specific
reactivity with non-HIV-1 antibodies. The present invention provides
methods of diagnosis, monitoring and treatment of HIV-related
diseases through the use of this antibody or related compounds".
The Company has licensed mAb 1F7 from the Sydney Kimmel
Cancer Centre and is conducting pre-clinical studies on macaques,
which are a biological model for HIV disease in humans. The
Company may file divisional applications in respect of certain
additional claims not allowed under the patent just issued.
The Company is waiting on responses from two laboratories in
respect of bioassays on blood plasma prior to selection of the
laboratory to analyze all of the plasma samples taken during its six
month Phase II pre-clinical trial of mAb 1F7. This study was
designed to evaluate the beneficial effects of mAb 1F7 on levels of
SHIV virus in the macaques and to test different SHIV clones. In an
earlier study, mAb 1F7 was shown to both strengthen and broaden
the immune response against the viral infection in the monkeys.
Data from this study will be integral to the application to the FDA
for approval of a human trial of mAb 1F7 under an Investigational
New Drug protocol, which is the next milestone.
The Company has closed a previously announced private
placement at $45,000 and will prepare for further financing in 1999
giving consideration to the patent just issued for mAb 1F7 and
anticipated results from the Phase 11 Pre-clinical Study.
"signed"
Victor J.E. Jones
President
Immune Network Research Ltd.
900 - 475 Howe Street
Vancouver, B.C., Canada V6C 2B3
Tel. (604) 689-3923
Fax. (604) 684-5854
immunenetwork.com
The Vancouver Stock Exchange has not reviewed and does not
accept responsibility for the adequacy or accuracy of the content of
this news release.
-----------------------
You received this message because you are registered as a
member of INR's NewsNOW! e-mail distribution list. If you would
like to be removed from this list, send a message to
webmaster@immunenetwork.com with the subject "Remove Me
from INR's NewsNOW! Service".
Do you know of anyone else who should become a list member?
|
